Pulmonary vasodilation by nitric oxide gas and prodrug aerosols in acute pulmonary hypertension

Journal of Applied Physiology

Volumn 84, Issue 2, 1998, Pages 435-441

  Adrie, Christophe ^a   Ichinose, Fumito ^a   Holzmann, Alexandra ^a   Keefer, Larry ^b   Hurford, William E ^a   Zapol, Warren M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Nitric oxide adducts; Sheep; Sodium nitroprusside

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PRODRUG; RINGER LACTATE SOLUTION;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG SELECTIVITY; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SHEEP; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

EID: 0031915550     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1998.84.2.435     Document Type: Article

References (34)

1. Bates, J. N., M. T. Baker, R. Guerra, Jr., and D. G. Harrison. Nitric oxide generation from nitroprusside by vascular tissue: evidence that reduction of the nitroprusside anion and cyanide release are required. Biochem. Pharmacol. 42, Suppl.: S157-S165, 1991.
2. Brent, B. N., H. J. Berger, R. A. Matthay, D. Mahler, L. Pytlik, and B. L. Zaret. Contrasting acute effects of vasodilators (nitroglycerin, nitroprusside, and hydralazine) on right ventricle performance in patients with chronic obstructive pulmonary disease and pulmonary hypertension: a combined radionuclide-hemodynamic study. Am. J. Cardiol. 51: 1682-1689, 1983.
3. Brown, G. Pharmocologic treatment of primary and secondary pulmonary hypertension. Pharmacotherapy 11: 137-156, 1991.
4. Clutton-Brock, J. Two cases of poisoning by contamination of nitrous oxide with the higher oxides of nitrogen during anaesthesia. Br. J. Anaesth. 39: 345-350, 1969.
5. Cohn, J. N., and L. P. Burke. Diagnosis and treatment. Drugs five years later, nitroprusside. Ann. Intern. Med. 91: 752-757, 1979.
6. Feelisch, M. The biochemical pathways of nitric oxide formation from nitrovasodilators: appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J. Cardiovasc. Pharmacol. 17, Suppl. 3: S25-S33, 1991.
7. Feelisch, M., and E. Noack. Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or non-heme iron. Eur. J. Pharmacol. 142: 465-469, 1987.
8. Fontijn, A., A. J. Sabadell, and R. J. Ronco. Homogeneous chemiluminescent measurement of nitric oxide with ozone. Implications for continuous selective monitoring of gaseous air pollutants. Anal. Chem. 42: 575-579, 1970.
9. Frostell, C., M.-D. Fratacci, J. C. Wain, R. Jones, and W. M. Zapol. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 83: 2038-2047, 1991.
10. Hampl, V., M. Tristani-Firousi, T. C. Hustell, and S. L. Archer. Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension. Cardiovasc. Res. 31: 55-62; 1996.
11. Hugod, C. Effect of exposure to 43 ppm nitric oxide, and 3.6 ppm nitrogen dioxide on rabbit lung. A light and electron microscopic study. Int. Arch. Occup. Environ. Health 42: 159-167, 1979.
12. Husain, M., C. Adrie, F. Ichinose, M. Kavosi, and W. M. Zapol. Exhaled nitric oxide as a marker for organic nitrate tolerance. Circulation 89: 2498-2502, 1994.
13. Ichinose, F., C. Adrie, W. E. Hurford, and W. M. Zapol. Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs. J. Appl. Physiol. 78: 1288-1295, 1995.
14. Ignarro, L. J. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 65: 1-21, 1989.
15. Jamieson, D. D., and K. M. Taylor. Comparison of the bronchodilator and vasodilator activity of sodium azide and sodium nitroprusside in the guinea-pig. Clin. Exp. Pharmacol. Physiol. 6: 515-525, 1979.
16. Kadowitz, P. J., P. Nandiwada, C. A. Gruetter, L. J. Ignarro, and A. L. Hyman. Pulmonary vasodilator responses to nitroprusside and nitroglycerin in the dog. J. Clin. Invest. 67: 893-902, 1981.
17. Keefer, L. K., R. W. Nims, K. M. Davies, and D. A. Wink. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol. 268: 281-293, 1996.
18. Klinke, W. P., and J. A. L. Gilbert. Diazoxide in primary pulmonary hypertension. N. Engl. J. Med. 302: 91-92, 1980.
19. Kochukoshy, K. N., T. W. Chick, and J. W. Jenne. The effect of nitroglycerin on gas exchange in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 111: 177-183, 1975.
20. Kreye, V. A. W., and E. Marquard. Comparison of sodium nitroprusside and isoprenaline aerosols in histamine-induced bronchial asthma of the guinea-pig. Naunyn Schmiedebergs Arch. Pharmacol. 306: 203-207, 1979.
21. McMahon, T. J., L. J. Ignarro, and P. J. Kadowitz. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J. Appl. Physiol. 74: 1704-1711, 1993.
22. Morley, T. F., S. J. Zappasodi, A. Belli, and J. C. Giudice. Pulmonary vasodilator therapy for chronic obstructive pulmonary disease and cor pulmonale. Chest 92: 71-76, 1987.
23. Pearl, R. G. Inhaled nitric oxide: the past, the present, and the future. Anesthesiology 78: 413-416, 1993.
24. Pepke-Zaba, J., T. W. Higenbottam, A. T. Dinh-Xuan, D. Stone, and J. Wallwork. Inhaled nitric oxide as a cause of selective vasodilatation in pulmonary hypertension. Lancet 338: 1173-1174, 1991.
25. Ragsdale, R. O., B. R. Karstetter, and R. S. Drago. Decomposition of the adducts of diethylamine and isopropylamine with nitrogen(II) oxide. Inorg. Chem. 4: 420-422, 1965.
26. Rossaint, R., K. J. Falke, F. López, K. Slama, U. Pison, and W. M. Zapol. Inhaled nitric oxide for the adult respiratory distress syndrome. N. Engl. J. Med. 328: 399-405, 1993.
27. Rubin, L. J., and R. H. Peter. Oral hydralazine therapy for primary pulmonary hypertension. N. Engl. J. Med. 302: 69-73, 1980.
28. Ruskin, J. N., and A. M. Hutter. Primary pulmonary hypertension treated with oral phentolamine. Ann. Intern. Med. 90: 772-774, 1979.
29. Stavert, D. M., and B. E. Lehnert. Nitrogen oxide and nitrogen dioxide as inducers of acute pulmonary injury when inhaled at relatively high concentrations for brief periods. Inhal. Toxicol. 2: 53-67, 1990.
30. Vanderford, P. A., J. Wong, R. Chang, L. K. Keefer, S. J. Soifer, and J. R. Fineman. Diethylamine/nitric oxide (NO) adduct, an NO donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs. J. Cardiovasc. Pharmacol. 23: 113-119, 1994.
31. Vesey, C. J., and P. V. Cole. Blood cyanide and thiocyanate concentrations produced by long-term therapy with sodium nitroprusside. Br. J. Anaesth. 57: 148-155, 1985.
32. Walmrath, D., T. Schneider, J. Pilch, F. Grimminger, and W. Seeger. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 342: 961-962, 1993.
33. 2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur. Surg. Res. 25: 329-340, 1993.
34. Zapol, W. M., M. A. Rie, M. Frikker, M. T. Snider, and D. A. Quinn. Pulmonary circulation during adult respiratory distress syndrome. In: Acute Respiratory Failure, edited by W. M. Zapol and K. J. Falke. New York: Dekker, 1985, vol. 24, p. 241-273. (Lung Biol. Health Dis. Ser.)